口服新型冠状病毒肺炎治疗新药——莫努匹韦

A novel oral drug for the treatment of corona virus disease 2019: molnupiravir

莫努匹韦(molnupiravir)是默克公司研发的口服抗新型冠状病毒肺炎新药,是β-D-N4-羟基胞苷(NHC)的小分子核糖核苷前体药物,其作用机制是干扰严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的遗传编码从而阻止病毒复制。美国食品药品管理局于2021年12年23日紧急批准莫努匹韦用于治疗成人轻型和普通型新型冠状病毒肺炎。本综述从莫努匹韦药理作用与作用机制、临床研究现状及进展等多方面讨论莫努匹韦在新型冠状病毒肺炎管理中的潜在有益作用、长期疗效和安全性。

Molnupiravir is a novel oral drug for the treatment of COVID-19 developed by Merck as a small-molecule ribonucleoside prodrug of β-D-N4-hydroxycytidine(NHC). Molnupiravir works by interfering with the genetic code of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) to prevent viral replication. The Food and Drug Administration(FDA)has granted emergency approval for molnupiravir for the treatment of non-hospitalized adults with mild or moderate COVID-19 on 23 December 2021. This review will discuss the potential beneficial effects,long-term efficacy,and safety of monupivir in the management of COVID-19 in terms of mechanism of action,current status,and progress of clinical studies.